The evidence is mixed2 supporting, 2 against, 3 worth knowing
Supporting
up 12% over twelve months
revenue grew 81% year on year in the quarter ending 2026-06-30
Against
trading 5% below its 200-day average
net margin has narrowed from 4.9% to 3.6% across four quarters
Worth knowing
the 50-day and 200-day averages disagree, which usually means a turn in progress rather than a trend to lean on
RSI at 24 is washed out — historically the better half of this site's measured edge comes from exactly this condition
the 5 scans it matches come from only 1 families — one signal wearing several hats rather than several signals
What would change this read: a close back above 45, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
How it has performed
price return over each window, measured against zero
What the scans say today
5 of 47 matched on 2026-08-21
MEDICO matches 5 of the 47 scans today, across 1 different kinds of evidence. Note how few kinds of evidence that is: several scans in one family are one signal wearing several hats, not several signals.
MEDICO trades at 26× trailing earnings, below its median of 39× over this window — 34% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
The Exchange has sought clarification from Medico Remedies Ltd on August 3, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
1d-1.25d-7.120d—
Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · Board meeting filings were typically -0.04pt vs the market over the next 5 sessions (n=5,458) · Order win filings were typically +0.20pt vs the market over the next 5 sessions (n=408)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 81% against the same quarter a year earlier
profit rose 38% year on year
revenue rose in 3 of the last 4 quarters
Going against it
net margin narrowed from 10.3% to 3.6%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · standalone
69
3
3
0.30
3.6%
Q4 FY26
2026-03-31 · standalone
57
8
6
0.71
10.3%
Q3 FY26
2025-12-31 · standalone
59
4
3
0.35
4.9%
Q2 FY26
2025-09-30 · standalone
53
3
3
0.31
4.9%
Q1 FY26
2025-06-30 · standalone
38
2
2
0.22
4.8%
Q4 FY25
2025-03-31 · standalone
41
6
4
0.52
10.5%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+0.7%
Versus 200-day average-4.8%
Below 52-week high-21.4%
Above 52-week low+30.2%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)23.9
Higher closes in last 52 of 5
Six-month return−5.24%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.